Population pharmacokinetics of cisplatin after 120-h infusion: Application to routine adaptive control with feedback

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 2, 2003, Pages 109-116

  Monjanel Mouterde, Suzanne ^a   Ciccolini, J ^a   Bagarry, D ^a   Zonta David, M ^a   Duffaud, F ^a   Favre, R ^a   Durand, A ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Bayesian; Cisplatin; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MEGADOSE; DRUG MONITORING; EWING SARCOMA; FEMALE; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; LUNG METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; OSTEOSARCOMA; OVARY CANCER; POPULATION RESEARCH; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BAYES THEOREM; CISPLATIN; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS;

EID: 0038331643     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00468.x     Document Type: Article

References (24)

1. Forastiere AA. (1994) Overview of platinum chemotherapy in head and neck cancer. Seminar in Oncology, 21, 20-27.
2. Williams CJ, Stewart L, Parmar M et al. (1992) Metaanalysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialist Group. Seminar in Oncology, 19, 121-128.
3. Benedetti Panici P, Greggi S, Scambia G et al. (1993) Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. Interational Journal of Gynecological Cancer, 3, 44-53.
4. Campbell AB, Kalman SM, Jacobs C. (1983) Plasma platinum levels: relationship to cis-platin dose and nephrotoxicity. Cancer Treatment Report, 67, 169-172.
5. Hogberg T, Glimelius B, Nygren P. (2001) A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncologica, 40, 340-360.
6. Ikeda K, Terashima M, Takiyama I et al. (1998) Pharmacokinetics of cisplatin in combined of cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Japanese Journal of Clinical Oncology, 28, 168-175.
7. Vermoken JB, Van Der Vijgh WJF, Klein I. (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clinical Pharmacology and Therapeutics, 39, 136-144.
8. Belliveau JB, Posner MR, Ferrari L. (1986) Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treatment Report, 70, 1215-1217.
9. Favre R, Charbit M, Rinaldi Y et al. (1988) Pharmacokinetics of phase IV studies for dosage adjustment. Bulletin Du Cancer, 75, 541.
10. Lennard L. (1999) Therapeutic drug monitoring of antimetabolic cytotoxic drugs. British Journal of Clinical Pharmacology, 47, 131-143.
11. Canal P, Chatelut E, Guichard S. (1998) Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs, 56, 1019-1038.
12. Bonetti A, Francheschi T, Apostoli P et al. (1995) Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors. Therapeutic Drug Monitoring, 17, 25-32.
13. Marquet P. (1999) Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects. Acta Clinica Belgica, 1, 2-12.
14. Cano JP, Catalin J, Blues-Charbit M. (1982) Platinum determination in plasma and urine by flameless atomic absorption spectrometry. Journal of Applied Toxicology, 2, 33-38.
15. Sheiner LB, Beal ST. (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503-512.
16. Iliadis A, Brown AC, Huggins ML. (1992) APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Computer Methods and Programs in Biomedicine, 38, 227-239.
17. Iliadis A, Bruno R, Cano JP. (1986) Steady-state dosage regimen calculations in linear pharmacokinetics. Journal de Pharmacie Clinique, 4, 167.
18. Favre R, Charbit M, Rinaldi Y et al. (1987) Optimization of cisplatin (CDDP) dosage regimen administered by continuous 5-day infusion using bayesian estimation. Proceedings of the AACR, 28, 1720.
19. Dechamp C, Rinaldi Y, Durand A et al. (1989) Etude pharmacocinétique du platine ultrafiltrable 'actif' au cours de perfusions continues à débit constant sur 5 jours de cisplatin avec adaptation de posologie. Bulletin Du Cancer, 76, 883.
20. Nagai N, Ogata H, Wada Y et al. (1998) Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with NONMEM program. Journal of Clinical Pharmacology, 38, 1025-1034.
21. Forastere AA, Belliveau JP, Goren MP et al. (1988) Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cisdiamminedichloroplatinum (II) in head and neck cancer patients. Cancer Research, 4, 1392-1398.
22. Guven K, Kittler H, Wolff K et al. (2001) Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Research, 11, 411-415.
23. Regine WF, Valentino J, Arnold SM et al. (2001) High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 19, 3333-3339.
24. Hesketh PJ, Roman A, Hesketh AM et al. (2000) Control of high-dose cisplatin-induced emesis with all-oral three-drug antiemetic regimen. Support Care Cancer, 8, 46-48.